Physician profile
Jian Li
NPI 1184705097
$12,618.60
in general payments reported to CMS, 2019-2025
39 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,236 · 2020: $1,204 · 2021: $1,048 · 2022: $1,739 · 2023: $2,054 · 2024: $2,655 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,274 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,273.50 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,104.04 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,294.61 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,054.04 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $841.59 | 2019-2025 | Dupixent |
| Genzyme Corporation | $817.53 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $816.91 | 2022-2025 | Acthar |
| Mylan Specialty L.P. | $728.97 | 2019-2024 | Yupelri |
| Insmed, INC. | $693.43 | 2019-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $591.83 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $452.24 | 2019-2025 | Opsumit, Opsynvi |
| Grifols USA, LLC | $370.35 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Merck Sharp & Dohme LLC | $234.14 | 2019-2025 | Keytruda, Capvaxive |
| Ani Pharmaceuticals, INC. | $209.83 | 2023-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $200.03 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $194.74 | 2019-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $153.46 | 2021-2025 | Tezspire |
| Philips North America LLC | $130.92 | 2019-2024 | (Ak6) Vest Therapy |
| Fisher & Paykel Healthcare INC | $100.09 | 2019-2023 | Fisher & Paykel Healthcare |
| Takeda Pharmaceuticals U.S.A., INC. | $87.66 | 2022-2024 | Glassia |
| United Therapeutics Corporation | $57.84 | 2022-2023 | Tyvaso, Orenitram |
| Teva Pharmaceuticals USA, INC. | $52.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.01 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $41.80 | 2019 | |
| Inogen, INC. | $32.58 | 2024 | |
| Edwards Lifesciences Corporation | $32.42 | 2021 | |
| Intuitive Surgical, INC. | $27.91 | 2023 | Da Vinci Surgical System |
| Ethicon INC. | $26.77 | 2024 | Monarch Platform |
| Baxter Healthcare | $25.39 | 2023 | Hillrom - Life 2000 Ventilation System |
| Allergan, INC. | $24.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.29 | 2021 | |
| Inspire Medical Systems, INC. | $23.87 | 2023 | Inspire |
| Melinta Therapeutics, LLC | $21.84 | 2023 | Rezzayo, Vabomere |
| Paratek Pharmaceuticals, INC. | $15.86 | 2022 | |
| Vifor Pharma, INC. | $15.46 | 2025 | Zemaira |
| Abbvie INC. | $15.20 | 2022 | |
| Portola Pharmaceuticals, LLC | $15.18 | 2019 | |
| Pfizer INC. | $13.91 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.